In this episode, guest host Deepak Bhatt, MD, MPH, FACC, offers a preview of some of the most important and clinically transformative studies being presented at the AHA 2022 Conference, November 5-7.

Day One includes two major studies on diuretics: primary results from the TRANSFORM HF Trial, examining the comparative effectiveness of torsemide versus furosemide in heart failure, and from the DCP Trial on chlorthalidone compared to hydrochlorothiazide for the prevention of cardiovascular events in patients with hypertension. Day One also includes a presentation on PROMINENT, a randomized trial of pemafibrate for triglyceride reduction in the prevention of cardiovascular disease.

Day Two includes a major and important presentation of data from EMPA-KIDNEY, examining empagliflozin and cardiovascular outcomes in patients with chronic kidney disease. QUARTET USA, a randomized control trial investigating the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension is also on the agenda. The primary results of ECMO-CS, a multicenter randomized trial on extracorporeal membrane oxygenation in the therapy of cardiogenic shock will be presented as well. 

The third and final day opens with BEST-CLI Trial, looking at the best endovascular versus best surgical therapy for patients with chronic limb-threatening ischemia, followed by a primary analysis from the RAPID Trial, focusing on self-administered etripamil for termination of spontaneous paroxysmal supraventricular tachycardia, followed by results from the Phase 2 NOVA Trial, examining the efficacy and safety of botulinum toxin type A for the prevention of postoperative atrial fibrillation in cardiac surgery patients.  There will also be a group of presentations on the treatment of persistent hypertension,  beginning with the top-line results from FRESH, looking at the first-in-class aminopeptidase-A inhibitor firibastat in treatment-resistant hypertension, followed by data from, PRECISION, a randomized controlled study including a withdrawal phase, investigating the sustained blood pressure-lowering effect with the dual endothelin receptor antagonist aprocitentan in resistant hypertension, followed in turn by the results from BrightHTN, a Phase 2 randomized double-blind placebo-controlled trial evaluating the efficacy and safety of baxdrostat in patients with treatment-resistant hypertension, and concluding with information on the 6-month primary results of SPYRAL HTN-ON, investigating the effect of radiofrequency renal denervation on blood pressure in the presence of antihypertensive drugs.  

AHA 2022 promises to be a rich and rewarding experience for those who can attend in person or participate virtually.

Subscribe to Eagle’s Eye View